[Bone marrow scintigraphy. Principles, clinical results and indications].
After consideration of the anatomical and physiological principles, the radiopharmaceuticals for scintigraphy of the erythropoietic, reticuloendothelial and-as a new development-of the granulopoietic bone marrow are introduced and compared. The data on performing and evaluating bone marrow scans are followed by the presentation of the clinical results. Staging and re-staging of malignant lymphomas, multiple myeloma, breast and lung cancer are considered to be the main indications. 99mTc-labelled monoclonal anti-NCA-95-antibodies are regarded as the radiopharmaceutical of choice.